Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
Soji Kakiuchi(The University of Tokyo), Yusuke Nakamura(National Institute of Biomedical Innovation, Health and Nutrition), Tatsuhiko Tsunoda(University of California San Diego), Chiyuki Furukawa, Nobuhisa Ishikawa(The University of Tokyo), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Masahiro Fukuoka(National Institute of Standards and Technology), Takashi Tsuruo(Chemotherapy Foundation), Nobuoki Kohno(Hiroshima University), Yataro Daigo(The University of Tokyo), Saburo Sone(Io Therapeutics (United States)), Seiji Yano(Kanazawa University Hospital)
Cited by 174
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Identification of FAP Locus Genes from Chromosome 5q21
|Science|1991|2.4k
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
|Science|1989|2.1k